Table 10.
Country | Gentamicin | Chloramphenicol | Ampicillin | Cefotaxime | Ceftazidime | Meropenem | Tigecycline | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Austria | 1,460 | 1.2 | 1,460 | 2.9 | 1,460 | 13.2 | 1,460 | 0.5 | 1,460 | 0.5 | 1,460 | 0 | 1,460 | 0 |
Belgium | 984 | 2.2 | 983 | 7.2 | 983 | 42.5 | 984 | 1.7 | 982 | 1.2 | 982 | 0 | – | – |
Cyprus | 105 | 4.8 | – | – | 106 | 24.5 | 34 | 2.9 | 106 | 0.9 | 102 | 0 | 1 | NA |
Denmark | 336 | 1.8 | 336 | 6.3 | 336 | 40.2 | 336 | 0.3 | 336 | 0.3 | 336 | 0 | 336 | 0.6 |
Estonia | 203 | 1.5 | 203 | 3.0 | 203 | 35.5 | 200 | 0 | 204 | 0 | 202 | 0 | – | – |
Finland | 240 | 0.8 | 240 | 4.6 | 240 | 25.0 | 240 | 2.1 | – | – | 240 | 0 | – | – |
France | 852 | 0.8 | 852 | 5.3 | 852 | 29.8 | 852 | 0.5 | 852 | 0.2 | 851 | 0 | 852 | 0.8 |
Germany a | 2,007 | 2.3 | 2,007 | 6.1 | 2,008 | 43.4 | 2,008 | 1.5 | 2,007 | 0.9 | 2,007 | 0 | – | – |
Greece | 246 | 0.8 | 246 | 1.2 | 246 | 8.1 | 246 | 0.8 | 246 | 0.8 | 245 | 0 | – | – |
Hungary a | 414 | 2.2 | 417 | 11.8 | 417 | 67.4 | 417 | 0.7 | 416 | 9.6 | 416 | 0 | – | – |
Ireland | 214 | 4.2 | 214 | 7.0 | 214 | 29.4 | 214 | 1.9 | 214 | 1.9 | 214 | 0 | 214 | 0.5 |
Italy | 66 | 4.5 | 66 | 9.1 | 66 | 47.0 | 66 | 0 | 66 | 0 | 66 | 0 | – | – |
Latvia a | – | – | – | – | 26 | 15.4 | 27 | 3.7 | – | – | – | – | – | – |
Lithuania a | 356 | 0.6 | 469 | 1.5 | 1,020 | 24.5 | 847 | 0.6 | 469 | 1.1 | 288 | 0 | – | – |
Luxembourg | 108 | 0.9 | 108 | 3.7 | 108 | 26.9 | 108 | 0 | 108 | 0.9 | 108 | 0 | – | – |
Malta a | – | – | – | – | 180 | 29.4 | 180 | 7.8 | 180 | 7.8 | 181 | 0 | – | – |
Netherlands | 927 | 2.3 | 927 | 7.8 | 927 | 29.4 | 927 | 1.2 | 927 | 1.1 | 927 | 0 | 927 | 1.2 |
Portugal | 308 | 1.3 | 308 | 7.5 | 308 | 52.9 | 308 | 0.3 | 308 | 0.3 | 308 | 0 | 308 | 0.3 |
Romania | 212 | 1.9 | 212 | 2.4 | 212 | 25.5 | 212 | 1.4 | 212 | 1.4 | 212 | 0 | – | – |
Slovakia a | – | – | 6 | NA | 790 | 8.2 | 201 | 2.0 | 8 | NA | 7 | 0 | – | – |
Slovenia | 311 | 0.3 | 311 | 0.6 | 311 | 11.6 | 311 | 0 | 311 | 0 | 311 | 0a | – | – |
Spain | 1,418 | 1.1 | 1,417 | 6.5 | 1,419 | 37.4 | 1,416 | 1.6 | 1,415 | 0.5 | 1,401 | 0 | – | – |
United Kingdom a | – | – | 2,095 | 11.6 | 3,454 | 23.1 | 1,295 | 1.0 | 749 | 4.4 | 844 | 0 | – | – |
Total (MSs 23) | 10,767 | 1.7 | 12,877 | 6.5 | 15,886 | 29.5 | 12,889 | 1.2 | 11,576 | 1.4 | 11,708 | 0 | 4,098 | 0.5 |
Iceland a | – | – | 23 | 0 | 23 | 60.9 | 1 | NA | – | – | – | – | – | – |
Norway | 223 | 2.2 | 84 | 16.7 | 223 | 20.6 | 223 | 0.9 | 223 | 0.9 | 223 | 0 | – | – |
Country | Nalidixic acid | Ciprofloxacinb | Azithromycin | Colistin | Sulfamethoxazolec | Trimethoprim | Co‐trimoxazole | Tetracycline | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Austria | 1,460 | 13.3 | 1,100 | 14.7 | – | – | – | – | 1,460 | 15.1 | 1,460 | 2.7 | – | – | 1,460 | 15.6 |
Belgium | 984 | 13.9 | 984 | 17.1 | 982 | 0.2 | – | – | 984 | 41.8 | 424 | 16.5 | – | – | 984 | 39.1 |
Cyprus | – | – | – | – | – | – | 68 | 0 | – | – | – | – | – | – | 35 | 31.4 |
Denmark | 336 | 3.0 | 336 | 4.5 | 336 | 1.2 | 336 | 3.9 | 336 | 37.8 | 336 | 6.0 | – | – | 336 | 38.1 |
Estonia | 153 | 43.1 | 203 | 36.0 | – | – | 202 | 0.5 | 203 | 35.0 | 203 | 30.5 | – | – | 202 | 37.6 |
Finland | 240 | 24.6 | 240 | 26.3 | – | – | – | – | – | – | 240 | 5.4 | – | – | 240 | 22.5 |
France | 852 | 10.3 | 851 | 11.0 | 852 | 1.1 | 852 | 7.5 | 852 | 41.4 | 852 | 6.2 | – | – | 852 | 30.9 |
Germany a | 2,006 | 11.7 | 2,007 | 2.2 | – | – | – | – | – | – | – | – | 2,006 | 7.2 | 2,003 | 27.1 |
Greece | 246 | 6.1 | 246 | 2.0 | – | – | – | – | 246 | 62.6 | 233 | 4.3 | – | – | 246 | 7.3 |
Hungary a | – | – | 419 | 6.0 | – | – | – | – | – | – | 417 | 6.5 | 417 | 12.5 | 417 | 68.3 |
Ireland | 214 | 18.7 | 214 | 22.9 | 214 | 2.3 | 52 | 0 | 214 | 27.1 | 214 | 7.9 | – | – | 214 | 31.3 |
Italy | 66 | 7.6 | 66 | 4.5 | – | – | – | – | 66 | 62.1 | 66 | 9.1 | 66 | 9.1 | 66 | 48.5 |
Latvia a | – | – | 27 | 0 | – | – | – | – | – | – | – | – | 1 | NA | – | – |
Lithuania a | 362 | 12.4 | 743 | 6.9 | – | – | – | – | – | – | 366 | 4.9 | 1,018 | 2.8 | 361 | 19.9 |
Luxembourg | – | – | 108 | 7.4 | – | – | – | – | 108 | 35.2 | 108 | 11.1 | 108 | 8.3 | 108 | 32.4 |
Malta a | – | – | 180 | 11.7 | – | – | – | – | – | – | – | – | – | – | – | – |
Netherlands | 927 | 14.3 | 927 | 16.2 | 927 | 0.8 | 927 | 7.8 | 927 | 29.6 | 927 | 5.6 | – | – | 927 | 28.7 |
Portugal | 308 | 17.9 | 308 | 14.6 | 308 | 1.0 | – | – | 308 | 74.0 | 308 | 22.4 | – | – | 308 | 53.2 |
Romania | 212 | 20.8 | 212 | 11.8 | – | – | – | – | 212 | 25.5 | 212 | 7.1 | 212 | 3.8 | 212 | 14.2 |
Slovakia a | – | – | 351 | 5.1 | – | – | – | – | – | – | – | – | 234 | 0.9 | 514 | 6.0 |
Slovenia | – | – | 310 | 14.5 | – | – | – | – | 311 | 18.0 | 311 | 3.5 | 311 | 1.9 | 311 | 13.2 |
Spain | 1,414 | 17.9 | 1,418 | 14.8 | – | – | – | – | 1,416 | 44.1 | 1,414 | 9.5 | – | – | 1,418 | 38.2 |
United Kingdom a | 1,096 | 15.1 | 3,572 | 10.2 | – | – | – | – | 499 | 21.2 | 1,813 | 8.6 | 814 | 10.6 | 633 | 29.9 |
Total (MSs 23) | 10,876 | 14.2 | 14,822 | 11.0 | 3,619 | 0.8 | 2,437 | 6.2 | 8,142 | 34.6 | 9,904 | 7.9 | 5,187 | 6.6 | 11,847 | 29.2 |
Iceland a | – | – | 23 | 4.3 | – | – | – | – | – | – | – | – | 23 | 0 | – | – |
Norway | – | – | 223 | 24.7 | 84 | 1.2 | – | – | – | – | – | – | 223 | 6.7 | 84 | 44.0 |
N: number of isolates tested; % Res: percentage of microbiologically resistant isolates (either interpreted as non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories); –: no data reported; NA: not applicable – if less than 10 isolates were tested, the percentage of resistance was not calculated; MS: Member State.
Data interpreted with clinical breakpoints.
Countries doing disk diffusion have replaced ciprofloxacin with pefloxacin when screening for fluoroquinolone resistance, as recommended by EUCAST.
Combined data on the class of sulfonamides and the substance sulfamethoxazole within this group.